Figure 1.
Figure 1. CD200 expression and association with event-free survival in patients with MM. (A) Affymetrix CD200 gene expression in normal memory B cells; normal polyclonal plasmablasts; normal BM plasma cells (BMPCs); purified myeloma cells from patients with multiple myeloma (MM); human myeloma cell lines; BM stromal cells; BM CD34 cells; purified BM CD15, CD14, and CD3 cells; and osteoclasts. (B) CD200 expression by primary MMCs or normal BMPCs was determined using a double labeling of primary MMCs with an FITC-conjugated anti-CD138 MoAb and a PE-conjugated anti-CD200 MoAb, or with FITC- or PE-conjugated isotype-matched control antibodies. (C) Kaplan-Meier plot of the event-free survival in patients with CD200present and CD200absent MMCs.

CD200expression and association with event-free survival in patients with MM. (A) Affymetrix CD200 gene expression in normal memory B cells; normal polyclonal plasmablasts; normal BM plasma cells (BMPCs); purified myeloma cells from patients with multiple myeloma (MM); human myeloma cell lines; BM stromal cells; BM CD34 cells; purified BM CD15, CD14, and CD3 cells; and osteoclasts. (B) CD200 expression by primary MMCs or normal BMPCs was determined using a double labeling of primary MMCs with an FITC-conjugated anti-CD138 MoAb and a PE-conjugated anti-CD200 MoAb, or with FITC- or PE-conjugated isotype-matched control antibodies. (C) Kaplan-Meier plot of the event-free survival in patients with CD200present and CD200absent MMCs.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal